All News
Filter News
Found 925 articles
-
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
5/25/2022
Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark.
-
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform
5/24/2022
Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra™ platform.
-
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
5/23/2022
Salubris Biotherapeutics, Inc. today reported new data from Cohort 2 of the ongoing Phase 1 study evaluating JK07, the Company’s lead drug candidate, for the treatment of heart failure with reduced ejection fraction (HFrEF).
-
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
5/5/2022
Scopus BioPharma Inc. today announced the appointment of Raphael (“Rafi”) Hofstein, Ph.D. to its Board of Directors (“Board”).
-
Galapagos demonstrates regulatory and commercial progress in Q1 2022
5/5/2022
Galapagos NV announced its first quarter 2022financial results, a year-to-date business updateand its outlook for the remainder of 2022.
-
Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
4/26/2022
Galapagos NV announces that theproposed resolutions presented at the extraordinary and annual shareholders’ meetingswere approved, including the implementation of a one-tier governance structure.
-
Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism
4/21/2022
Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces the completion of a seed funding round.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Jyseleca® approved in Japan for ulcerative colitis
3/28/2022
Galapagos NV reports that Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced the approval by the Japanese Ministry of Health, Labour and Welfare, of a second indication for Jyseleca, a once-daily, oral, JAK1 preferentialinhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis.
-
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
3/24/2022
Galapagos NV published its annual report for the financial year 2021 and announces extraordinary and annual shareholders’ meetings to be held sequentially on Tuesday 26 April 2022 at 1:00p.m. and 2:00p.m., respectively, at the registered office of the Company.
-
Galapagos increases share capital through subscription right exercises - Mar 18, 2022
3/18/2022
Galapagos issued 95,500 new ordinary shares on 18 March 2022, for a total capital increase of €2,159,600.00.
-
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/15/2022
Ryvu Therapeutics reported financial results for the fourth quarter and the full year ended December 31, 2021, and provided a corporate update.
-
Galapagos 2021 results set stage for future growth
2/24/2022
Galapagos NV presents financial results 2021, reviews key events forthe company, and provides outlook for 2022.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Ermium Therapeutics Announces the Formation of a Scientific Advisory Board
2/3/2022
Ermium Therapeutics is announcing today the establishment of a scientific advisory board.
-
Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
2/2/2022
Galapagos NV will present data at the European Crohn’s and Colitis Organization annual congress taking place 16-19 February 2022.
-
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
2/1/2022
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2021.
-
Galapagos NV has appointed Dr. Paul Stoffelsas as its new chief executive officer, replacing Onno van de Stolpe who is retiring.
-
Galapagos appoints Paul Stoffels as Chief Executive Officer
1/26/2022
Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffelsas Chief Executive Officer (CEO),effective April 1, 2022.
-
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
1/18/2022
Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca®(filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain.